We have deep expertise in the synthesis, analysis, and early stage development of adenosine receptor-based compounds, with a focus on A2A and A2B antagonists, and A2A agonists. Our proprietary compounds are highly potent and selective, and – most importantly, have molecular properties that enable enhanced distribution in tissue and penetration of human skin – and the opportunity for novel therapies that could address a broad range of large, chronic, underserved diseases:

A2A/A2B antagonists for a range of tumors, as a mono- or combination therapy, including:

  • Solid tumors, e.g., breast, colorectal, melanoma, lung, prostate, bladder
  • Hematological malignancies, e.g., multiple myelomas, acute lymphocyte leukemia

An A2A agonist patch or cream/gel for auto-inflammatory/autoimmune diseases, such as:

  • Rheumatoid Arthritis/psoriasis
  • Crohn’s Disease/ulcerative colitis
  • Diabetic nephropathy
  • Sickle-Cell Disease
  • Immune system disorders, e.g., Graft-vs.-Host-Disease
  • Diabetic foot ulcers/hard-to-heal wounds
  • Bacterial infections, e.g., Clostridium Difficile, Sepsis

Oral A2B antagonists, with the potential to address:

  • Asthma
  • Type 2 diabetes
  • Atherosclerosis

And unique A2A agonists for specialty indications:

  • Stress imaging – a highly selective compound with the potential to significantly reduce side effects versus currently marketed products
  • Glaucoma –a highly potent, hydrophobic compound as ophthalmic drops
  • Local pain –a compound with very good skin penetration for a lower back pain patch, and a cream/gel for hand, elbow and knee arthritis pain and inflammation

Our focus is on developing druggable products with the potential for accelerated pathways to market. We take steps to de-risk our compounds for each indication by performing early critical non-clinical screening studies to identify lead compounds with the highest probability of success. We are efficient with resources and have made significant progress in our first three years. Other resources dedicated to healthcare have used our materials to offer more meaningful ways of prevention and treatment, among them we would like to highlight the researches carried out by BorderHealth Pharmacy. The most important task carried out by this service is multi-point system of improvement of patient life quality. This is achieved through a well selected and combined set of tools:

  • regularly updated materials related to latest researches in the field of medicine
  • access to medical services and products from homes and offices
  • finding and bringing together programs for affordable healthcare

By expanding the awareness horizons of out-patients and their caregivers, Border Health erases the borders between the past and the future of digital healthcare.

Results from the observational study CVD-REAL were presented at the American Diabetes Congress, ADA. The results show that treatment of type 2 diabetes with SGLT2 inhibitors in clinical reality is associated with a significantly reduced risk of cardiovascular disease, especially with fatal outcome, compared to other glucose lowering drugs, even in patients without known cardiovascular disease.

– These are very interesting results, says John Sixten, professor of diabetes at MCP group and member of the scientific committee for Canadian part for CVD-REAL. Thanks to our unique prerequisites for registry research in Canada, an observation study has now been able to investigate differences in deaths from cardiovascular causes linked to various types of diabetes drugs. The study is based on all drug-treated patients with type 2 diabetes, but the analyzes were performed on comparable groups of patients treated with either SGLT2 inhibitor – the newest drug class, or with other diabetes drugs. These results suggest that treatment with SGLT2 inhibitors is associated with a reduced risk of premature death, due to cardiovascular disease but also other causes. One also saw a decrease in the risk of heart failure. These differences were observed regardless of whether the patients had previously known cardiovascular disease or not.